Download PDF
CC BY-NC-ND 4.0 · Rev Bras Ortop (Sao Paulo) 2023; 58(03): 378-387
DOI: 10.1055/s-0042-1748947
Revisão Sistemática e Metanálise
Quadril

Efficacy of Ibuprofen after Total Hip Arthroplasty to Prevent Heterotopic Ossification: Systematic Review and Meta-Analysis[*]

Article in several languages: português | English
Muhammad Ali Tariq 
1   Departamento de Cirurgia Ortopédica, Dow International Medical College, Karachi, Paquistão
,
Bilal Ahmed 
1   Departamento de Cirurgia Ortopédica, Dow International Medical College, Karachi, Paquistão
,
Shehryar Shaikh 
1   Departamento de Cirurgia Ortopédica, Dow International Medical College, Karachi, Paquistão
,
Hamza Amin 
2   Departamento de Cirurgia Ortopédica, Dr. Ruth K. M. Pfau Civil Hospital, Karachi, Paquistão
,
Syed Uzair Ali 
1   Departamento de Cirurgia Ortopédica, Dow International Medical College, Karachi, Paquistão
› Author Affiliations Financial Support No grant or other financial support has been received for conducting this study.
› Further Information
   Permissions and Reprints

Abstract

The objective of this study was to conduct a systematic review and meta-analysis of relevant randomized control trials (RCTs) to determine the role of ibuprofen, as well as the optimum dose and duration of therapy, in preventing the incidence of heterotopic ossification (HO) after primary total hip arthroplasty (THA). A literature search was performed using the PubMed/MEDLINE and Cochrane Library databases for RCTs that compared the use of ibuprofen versus placebo as prophylaxis for HO in patients after THA. The main outcomes for this study were overall occurrence of HO, occurrence according to the Brooker classification, and gastrointestinal complications. A total of 27 potential articles were identified from the database. Eventually, four trials with 1,153 patients were included in the final analysis. When compared with placebo, the use of ibuprofen is associated with a reduction in the incidence of HO at the 3- and 12-month follow-up appointments, as well as the incidence of Brooker II and III HO (p < 0.05). However, there was no significant difference between the ibuprofen and placebo groups in terms of treatment discontinuation due to gastrointestinal complications or the incidence of Brooker I and IV HO (p > 0.05). The existing data indicates that ibuprofen is safe and efficacious in reducing the total incidence of HO along with Brooker II and III HO at follow-up. However, due to the small number of studies, the conclusions are limited; therefore, more high-quality clinical trials are required to develop guidelines for optimal dose and duration of therapy.

Keywords

arthroplasty, replacement, hip - ossification heterotopic - ibuprofen - meta-analysis

* Work developed at Department of Orthopaedic Surgery, Dow International Medical College, Karachi, Pakistan




Publication History

Received: 01 September 2021

Accepted: 14 March 2022

Article published online:
27 June 2022

© 2022. Sociedade Brasileira de Ortopedia e Traumatologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • Referências

  • 1 Varacallo M, Chakravarty R, Denehy K, Star A. Joint perception and patient perceived satisfaction after total hip and knee arthroplasty in the American population. J Orthop 2018; 15 (02) 495-499
    CrossrefPubMedGoogle Scholar
  • 2 Hansson S, Bülow E, Garland A, Kärrholm J, Rogmark C. More hip complications after total hip arthroplasty than after hemi-arthroplasty as hip fracture treatment: analysis of 5,815 matched pairs in the Swedish Hip Arthroplasty Register. Acta Orthop 2020; 91 (02) 133-138
    CrossrefPubMedGoogle Scholar
  • 3 Healy WL, Iorio R, Clair AJ, Pellegrini VD, Della Valle CJ, Berend KR. Complications of Total Hip Arthroplasty: Standardized List, Definitions, and Stratification Developed by The Hip Society. Clin Orthop Relat Res 2016; 474 (02) 357-364
    CrossrefPubMedGoogle Scholar
  • 4 Rosteius T, Rausch V, Pätzholz S. et al. Incidence and risk factors for heterotopic ossification following periprosthetic joint infection of the hip. Arch Orthop Trauma Surg 2019; 139 (09) 1307-1314
    CrossrefPubMedGoogle Scholar
  • 5 Brooker AF, Bowerman JW, Robinson RA, Riley Jr LHJ. Ectopic ossification following total hip replacement. Incidence and a method of classification. J Bone Joint Surg Am 1973; 55 (08) 1629-1632
    CrossrefPubMedGoogle Scholar
  • 6 Zhu Y, Zhang F, Chen W, Zhang Q, Liu S, Zhang Y. Incidence and risk factors for heterotopic ossification after total hip arthroplasty: a meta-analysis. Arch Orthop Trauma Surg 2015; 135 (09) 1307-1314
    CrossrefPubMedGoogle Scholar
  • 7 Manrique J, Alijanipour P, Heller S, Dove M, Parvizi J. Increased Risk of Heterotopic Ossification Following Revision Hip Arthroplasty for Periprosthetic Joint Infection. Arch Bone Jt Surg 2018; 6 (06) 486-491
    PubMedGoogle Scholar
  • 8 Eggli S, Woo A. Risk factors for heterotopic ossification in total hip arthroplasty. Arch Orthop Trauma Surg 2001; 121 (09) 531-535
    CrossrefPubMedGoogle Scholar
  • 9 Rüdiger HA, Dittrich M, Robinson J. et al. The Impact of Heterotopic Ossification on Self-Reported Outcomes After Total Hip Arthroplasty Using the Direct Anterior Approach. J Bone Joint Surg Am 2020; 102 (Suppl. 02) 91-98
    CrossrefPubMedGoogle Scholar
  • 10 van Erp JHJ, Massier JRA, Truijen S, Bekkers JEJ, Snijders TE, de Gast A. Heterotopic ossification in primary total hip arthroplasty using the posterolateral compared to the direct lateral approach. Arch Orthop Trauma Surg 2021; 141 (07) 1253-1259
    CrossrefPubMedGoogle Scholar
  • 11 Shapira J, Yelton MJ, Chen JW. et al. Efficacy of NSAIDs versus radiotherapy for heterotopic ossification prophylaxis following total hip arthroplasty in high-risk patients: a systematic review and meta-analysis. Hip Int 2021; 1120700021991115
    Google Scholar
  • 12 Rosenberg DM, Onderdonk B, Majeed NK. et al. Radiation-Induced Sarcoma After Heterotopic Ossification Prophylaxis: A Case Report. JBJS Case Connect 2019; 9 (04) e0146
    CrossrefPubMedGoogle Scholar
  • 13 Strauss JB, Chen SS, Shah AP, Coon AB, Dickler A. Cost of radiotherapy versus NSAID administration for prevention of heterotopic ossification after total hip arthroplasty. Int J Radiat Oncol Biol Phys 2008; 71 (05) 1460-1464
    CrossrefPubMedGoogle Scholar
  • 14 Kan SL, Yang B, Ning GZ. et al. Nonsteroidal Anti-inflammatory Drugs as Prophylaxis for Heterotopic Ossification after Total Hip Arthroplasty: A Systematic Review and Meta-Analysis. Medicine (Baltimore) 2015; 94 (18) e828
    CrossrefPubMedGoogle Scholar
  • 15 Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339: b2535
    CrossrefPubMedGoogle Scholar
  • 16 Higgins JP, Altman DG, Gøtzsche PC. et al; Cochrane Bias Methods Group, Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928
    Google Scholar
  • 17 DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7 (03) 177-188
    CrossrefPubMedGoogle Scholar
  • 18 Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327 (7414): 557-560
    CrossrefPubMedGoogle Scholar
  • 19 Fransen M, Anderson C, Douglas J. et al; HIPAID Collaborative Group. Safety and efficacy of routine postoperative ibuprofen for pain and disability related to ectopic bone formation after hip replacement surgery (HIPAID): randomised controlled trial. BMJ 2006; 333 (7567): 519
    CrossrefPubMedGoogle Scholar
  • 20 Persson PE, Sodemann B, Nilsson OS. Preventive effects of ibuprofen on periarticular heterotopic ossification after total hip arthroplasty. A randomized double-blind prospective study of treatment time. Acta Orthop Scand 1998; 69 (02) 111-115
    CrossrefPubMedGoogle Scholar
  • 21 Ahrengart L, Blomgren G, Törnkvist H. Short-term ibuprofen to prevent ossification after hip arthroplasty. No effects in a prospective randomized study of 47 arthrosis cases. Acta Orthop Scand 1994; 65 (02) 139-141
    CrossrefPubMedGoogle Scholar
  • 22 Elmstedt E, Lindholm TS, Nilsson OS, Törnkvist H. Effect of ibuprofen on heterotopic ossification after hip replacement. Acta Orthop Scand 1985; 56 (01) 25-27
    CrossrefPubMedGoogle Scholar
  • 23 Sterne JA, Sutton AJ, Ioannidis JP. et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011; 343: d4002
    CrossrefPubMedGoogle Scholar
  • 24 Nauth A, Giles E, Potter BK. et al. Heterotopic ossification in orthopaedic trauma. J Orthop Trauma 2012; 26 (12) 684-688
    CrossrefPubMedGoogle Scholar
  • 25 Meyers C, Lisiecki J, Miller S. et al. Heterotopic Ossification: A Comprehensive Review. JBMR Plus 2019; 3 (04) e10172
    CrossrefPubMedGoogle Scholar
  • 26 Firoozabadi R, Alton T, Sagi HC. Heterotopic Ossification in Acetabular Fracture Surgery. J Am Acad Orthop Surg 2017; 25 (02) 117-124
    CrossrefPubMedGoogle Scholar
  • 27 Gebuhr P, Soelberg M, Orsnes T, Wilbek H. Naproxen prevention of heterotopic ossification after hip arthroplasty. A prospective control study of 55 patients. Acta Orthop Scand 1991; 62 (03) 226-229
    CrossrefPubMedGoogle Scholar
  • 28 Wahlström O, Risto O, Djerf K, Hammerby S. Heterotopic bone formation prevented by diclofenac. Prospective study of 100 hip arthroplasties. Acta Orthop Scand 1991; 62 (05) 419-421
    CrossrefPubMedGoogle Scholar
  • 29 Grohs JG, Schmidt M, Wanivenhaus A. Selective COX-2 inhibitor versus indomethacin for the prevention of heterotopic ossification after hip replacement: a double-blind randomized trial of 100 patients with 1-year follow-up. Acta Orthop 2007; 78 (01) 95-98
    CrossrefPubMedGoogle Scholar
  • 30 Legenstein R, Bösch P, Ungersböck A. Indomethacin versus meloxicam for prevention of heterotopic ossification after total hip arthroplasty. Arch Orthop Trauma Surg 2003; 123 (2-3): 91-94
    CrossrefPubMedGoogle Scholar
  • 31 Sagi HC, Jordan CJ, Barei DP, Serrano-Riera R, Steverson B. Indomethacin prophylaxis for heterotopic ossification after acetabular fracture surgery increases the risk for nonunion of the posterior wall. J Orthop Trauma 2014; 28 (07) 377-383
    CrossrefPubMedGoogle Scholar
  • 32 Zhu XT, Chen L, Lin JH. Selective COX-2 inhibitor versus non-selective COX-2 inhibitor for the prevention of heterotopic ossification after total hip arthroplasty: A meta-analysis. Medicine (Baltimore) 2018; 97 (31) e11649
    CrossrefPubMedGoogle Scholar
  • 33 Macfarlane RJ, Ng BH, Gamie Z. et al. Pharmacological treatment of heterotopic ossification following hip and acetabular surgery. Expert Opin Pharmacother 2008; 9 (05) 767-786
    CrossrefPubMedGoogle Scholar
  • 34 Walker C. Are All Oral COX-2 Selective Inhibitors the Same? A Consideration of Celecoxib, Etoricoxib, and Diclofenac. Int J Rheumatol 2018; 2018: 1302835
    CrossrefPubMedGoogle Scholar
  • 35 Sibbald B. Rofecoxib (Vioxx) voluntarily withdrawn from market. CMAJ 2004; 171 (09) 1027-1028
    CrossrefPubMedGoogle Scholar
  • 36 Solomon SD, Wittes J, Finn PV. et al; Cross Trial Safety Assessment Group. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 2008; 117 (16) 2104-2113
    CrossrefPubMedGoogle Scholar
  • 37 Hug KT, Alton TB, Gee AO. Classifications in brief: Brooker classification of heterotopic ossification after total hip arthroplasty. Clin Orthop Relat Res 2015; 473 (06) 2154-2157
    CrossrefPubMedGoogle Scholar
  • 38 Mary Jiayi T, Linda P, Michael P. et al. Potential discrepancy between plain films and CT scans in Brooker classification of heterotopic ossification. Br J Radiol 2017; 90 (1080): 20170263
    CrossrefPubMedGoogle Scholar
  • 39 Nilsdotter A, Bremander A. Measures of hip function and symptoms: Harris Hip Score (HHS), Hip Disability and Osteoarthritis Outcome Score (HOOS), Oxford Hip Score (OHS), Lequesne Index of Severity for Osteoarthritis of the Hip (LISOH), and American Academy of Orthopedic Surgeons (AAOS) Hip and Knee Questionnaire. Arthritis Care Res (Hoboken) 2011; 63 (Suppl. 11) S200-S207
    CrossrefPubMedGoogle Scholar